Easywell Biomedicals, Inc. (TPEX:1799)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
43.50
+2.20 (5.33%)
Apr 17, 2026, 1:30 PM CST
Market Cap5.42B -38.7%
Revenue (ttm)597.41M +10.5%
Net Income-73.14M
EPS-0.59
Shares Out124.69M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume656,477
Average Volume296,803
Open43.00
Previous Close41.30
Day's Range41.50 - 44.60
52-Week Range27.65 - 68.30
Beta-0.06
RSI66.14
Earnings DateMay 12, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 1799
Full Company Profile

Financial Performance

In 2025, Easywell Biomedicals's revenue was 597.41 million, an increase of 10.54% compared to the previous year's 540.44 million. Losses were -73.14 million, -24.96% less than in 2024.

Financial Statements